In Re Cassava Sciences, Inc. Securities Litigation

CourtDistrict Court, W.D. Texas
DecidedJanuary 2, 2023
Docket1:21-cv-00751
StatusUnknown

This text of In Re Cassava Sciences, Inc. Securities Litigation (In Re Cassava Sciences, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Cassava Sciences, Inc. Securities Litigation, (W.D. Tex. 2023).

Opinion

UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

IN RE CASSAVA SCIENCES, INC. § SECURITIES LITIGATION § ________________________________ § § Master File No. 1:21-cv-00751-DAE This Document Relates to: § § CLASS ACTION ALL ACTIONS. § ________________________________ § __

ORDER

Now before the Court are Plaintiff’s Opposed Motion for Partial Relief From the PSLRA Discovery Stay, filed September 30, 2022 (Dkt. 72); Defendants’ Opposition to Plaintiffs’ Motion for Partial Relief From the PSLRA Discovery Stay, filed October 25, 2022 (Dkt. 82); and Plaintiff’s Reply in Further Support of Plaintiff’s Opposed Motion for Partial Relief From the PSLRA Discovery Stay, filed November 4, 2022 (Dkt. 83).1 I. Background Named Plaintiffs Mohammad Bozorgi, Ken Calderone, and Manohar K. Rao bring this securities fraud class action lawsuit, on behalf of themselves and all others similarly situated, against Cassava Sciences, Inc., and Cassava executives Remi Barbier, Eric Schoen, Lindsay Burns, and Nadav Friedmann (collectively, “Defendants”). Cassava is a biotechnology company based in Austin, Texas, that is developing an investigational drug, simufilam, to treat Alzheimer’s disease. Plaintiffs’ Consolidated Complaint (Dkt. 68) ¶¶ 1, 56, 73. On August 18, 2021, a “Citizen Petition” was filed with the Food and Drug Administration accusing Cassava of research misconduct related

1 By Text Order entered October 4, 2022, the District Court referred the motion to this Magistrate Judge for resolution, pursuant to 28 U.S.C. § 636(b)(1)(A), Federal Rule of Civil Procedure 72, and Rule 1(c) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas. to simufilam. Id. ¶¶ 105, 117. The U.S. Securities and Exchange Commission and U.S. Department of Justice began investigating and requested certain documents from Cassava in the fall of 2021. Id. ¶ 5. Defendants deny any wrongdoing. Plaintiffs allege that they purchased Cassava securities between September 14, 2020 and July 26, 2022 (the “Class Period”) and suffered damages as a result of Defendants’ federal

securities law violations, false and misleading statements, and material omissions. Plaintiffs allege that “Defendants engaged in a fraudulent scheme to materially mislead investors regarding the prospects for Cassava’s primary product candidate, a purported treatment for Alzheimer’s disease, simufilam.” Id. ¶ 80. Plaintiffs assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 (“PSLRA”), and Rule 10b-5, 17 C.F.R. §240.10b-5. On June 30, 2022, the District Court consolidated three other related shareholder actions2 against Cassava and its executives with and into this action. Dkt. 58. Plaintiffs filed their Consolidated Complaint on August 18, 2022. Dkt. 68. On October 25, 2022, Defendants filed a

Motion to Dismiss Plaintiffs’ lawsuit under Federal Rule of Civil Procedure 12(b)(6), which is pending. Dkt. 81. Section 78u-4(b)(3)(B) of the PSLRA mandates an automatic stay of “all discovery” during the pendency of a motion to dismiss. 15 U.S.C. § 78u-4(b)(3)(B). Accordingly, discovery in this case is stayed pending resolution of Defendants’ Motion to Dismiss. Plaintiffs now move the Court to lift the discovery stay for the limited purpose of allowing them to obtain (1) documents Cassava produced in a separate non-PSLRA stockholder derivative action pending in the Delaware Court of Chancery accusing Casava and its executives of breach of fiduciary duty and unjust enrichment,3 and (2) “documents, interviews, and information”

2 1:21-cv-760-DAE, 1:21-cv-856-DAE, and 1:21-cv-971-DAE. 3 Calamore v. Barbier, No. 2022-0737-MTZ (Del. Ch. Aug. 24, 2022) (Dkt. 73-2). Cassava provided to the SEC, DOJ, and National Institutes of Health during those agencies’ investigations. Dkt. 72 at 5. Defendants oppose the motion. II. Legal Standards Congress passed the PSLRA in 1997 “in response to an increase in securities fraud lawsuits perceived as frivolous, including shareholder strike suits and other meritless lawsuits.” Newby v.

Enron Corp., 338 F.3d 467, 471 (5th Cir. 2003). The statute provides for an automatic stay of discovery in Section 78u-4(b)(3)(B): In any private action arising under this chapter, all discovery and other proceedings shall be stayed during the pendency of any motion to dismiss, unless the court finds upon the motion of any party that particularized discovery is necessary to preserve evidence or to prevent undue prejudice to that party. Congress enacted this provision “to prevent costly ‘extensive discovery and disruption of normal business activities’ until a court could determine whether a filed suit had merit, by ruling on the defendant’s motion to dismiss.” Newby, 338 F.3d at 471 (citation omitted). The automatic discovery stay also protects “defendants from plaintiffs who would use discovery to substantiate an initially frivolous complaint.” Id.; see also SG Cowen Sec. Corp. v. U.S. Dist. Ct. for N. Dist. of Cal., 189 F.3d 909, 912-13 (9th Cir. 1999) (“The ‘Stay of Discovery] provision of the Act clearly contemplates that ‘discovery should be permitted in securities class actions only after the court has sustained the legal sufficiency of the complaint.’”). The movant bears the burden to show the stay should be lifted. Davis v. Duncan Energy Partners L.P., 801 F. Supp. 2d 589, 592 (S.D. Tex. 2011). “The burden of establishing the need for a partial lifting of the discovery stay, not surprisingly, is a heavy one.” In re Fannie Mae Sec. Litig., 362 F. Supp. 2d 37, 38 (D.D.C. 2005). III. Analysis To meet their burden to lift the automatic discovery stay under the PSLRA, Plaintiffs must prove either that the requested discovery is needed to (1) preserve evidence or (2) prevent undue prejudice. 15 U.S.C. § 78u-4(b)(3)(B). Plaintiffs rely only on the latter exception, arguing that the Court should lift the stay to prevent undue prejudice. While the PSLRA does not define “undue prejudice,” district courts in this Circuit have construed the “undue prejudice” standard as “improper or unfair treatment amounting to something less than irreparable harm.” Texas Pac. Land Tr. v. Oliver, No. 3:19-CV-1224-B, 2019 WL

3387767, at *4 (N.D. Tex. July 26, 2019); Alaska Laborers Emps. Ret. Fund v. Mays Clear Channel Commc’ns, Inc., No. SA-07-CA-0042-RF, 2007 WL 9710527, at *4 (W.D. Tex. Feb. 14, 2007) (same). “Prejudice caused by the delay inherent in the PSLRA’s discovery stay cannot be ‘undue’ prejudice because it is prejudice which is neither improper nor unfair.” Barrett v. Wilson, No. 4:11-CV-02852, 2011 WL 13134638, at *3 (S.D. Tex. Aug. 15, 2011) (quoting In re CFS, 179 F. Supp. 2d 1260, 1265 (N. D. Okla. 2001)). “Instead, exceptional circumstances are required to lift the stay.” Alaska Laborers, 2007 WL 9710527, at *4.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Newby v. Enron Corporation
338 F.3d 467 (Fifth Circuit, 2003)
In Re American Funds Securities Litigation
493 F. Supp. 2d 1103 (C.D. California, 2007)
Davis v. Duncan Energy Partners L.P.
801 F. Supp. 2d 589 (S.D. Texas, 2011)
Mori v. Saito
802 F. Supp. 2d 520 (S.D. New York, 2011)
In Re Fannie Mae Securities Litigation
362 F. Supp. 2d 37 (District of Columbia, 2005)
In Re CFS-Related Securities Fraud Litigation
179 F. Supp. 2d 1260 (N.D. Oklahoma, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
In Re Cassava Sciences, Inc. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-cassava-sciences-inc-securities-litigation-txwd-2023.